Wrinkles

... PharmaLive: Inamed's Phase 3 Study Results for Juvederm to Be Presented at the 64th Annual Meeting of the American Academy of Dermatology REGISTERED USERS TODAY ON PHARMALIVE.COM Inamed's Phase 3 Study Results for Juvederm to Be Presented at the 64th Annual Meeting of the American Academy of Dermatology Key Phase 3 Study Results for Three Juvederm(TM) Formulations to Be Highlighted; Data Shows Superior Efficacy and Duration of Effect Versus Zyplast(R) SANTA BARBARA, Calif.-(BUSINESS WIRE)-Mar 3, 2006 - Inamed Corporation (NASDAQ:IMDC) announced today that Phase 3 clinical data for the three formulations of Juvederm(TM) (Juvederm(TM) 24HV, Juvederm(TM) 30HV, and Juvederm(TM) 30), a next generation, non-animal, cross linked hyaluronic acid based dermal filler, will be presented at the 64th Annual Meeting of the American Academy of Dermatology in San Francisco, California.

The Juvederm Phase 3 data, which shows superior efficacy and duration of effect versus Zyplast(R) (cross-linked bovine collagen), will be presented today by Gary Monheit, M.D., Associate Clinical Professor of Dermatology and Ophthalmology, University of Alabama at Birmingham and President of the American Society for Dermatologic Surgery, and will also be displayed at the poster exhibit at the Moscone Convention Center beginning at 1:00 p.m.

on Friday, March 3.

Based on the independent investigators' assessments, the percent of patients improved with Juvederm at 6 months was in the range of 81% - 90% ...

Read more...